Gan X T, Cook M A, Moffat M P, Karmazyn M
Department of Pharmacology and Toxicology, University of Western Ontario, London, Canada.
J Mol Cell Cardiol. 1996 May;28(5):1165-76. doi: 10.1006/jmcc.1996.0107.
We previously reported that adenosine A1 receptor activation protects against the cardiodepressant effects of hydrogen peroxide in isolated rat hearts. The present study examined whether a transient ischemic period of 5 min duration, which preconditions the heart against ischemic and reperfusion-induced dysfunction, can bestow protection against 30-min exposure to hydrogen peroxide in isolated rat hearts. Transient ischemia on its own failed to alter the cardiac response to hydrogen peroxide. However, when transient ischemia was carried out in the presence of the nucleoside transport inhibitor S-(4-Nitrobenzyl)-6-thioguanosine and the adenosine deaminase inhibitor erythro-9-(2-Hydroxy-3-nonyl)adenine, a significant attenuation of the hydrogen peroxide-induced loss in contractility was evident and this was associated with significant preservation of tissue glycogen content. The protective effect of the transient ischemia/drug combination on both functional changes and glycogen levels was abolished by the adenosine A1 receptor antagonist 8-cyclopentyl-1, 3-dipropylxanthine as well as by glibenclamide, a blocker of the ATP-sensitive potassium channel (KATP). To further assess the role of glycogen in the protection against hydrogen peroxide, we compared the effects of the adenosine A1 agonist N6-cyclopentyl adenosine (CPA) and insulin. While both treatments protected against hydrogen peroxide the effect of insulin was superior to any other treatment. Moreover, while all protective modalities preserved glycogen stores after hydrogen peroxide treatment, the protection afforded by insulin was also associated with significantly elevated glycogen levels prior to hydrogen peroxide administration. No protection by either CPA or insulin was evident in the absence of exogenous glucose. Taken together, our results demonstrate that a brief period of ischemia with concomitant administration of agents which increase interstitial adenosine levels protects against hydrogen peroxide toxicity. The effect is mediated by activation of adenosine A1 receptors and is linked to KATP stimulation. Moreover, our results are strongly suggestive of an important role of glycogen preservation in bestowing protective effects against hydrogen peroxide cardiotoxicity.
我们之前报道过,腺苷A1受体激活可保护离体大鼠心脏免受过氧化氢的心脏抑制作用。本研究检测了持续5分钟的短暂缺血期(该缺血期可使心脏对缺血及再灌注诱导的功能障碍产生预处理)是否能使离体大鼠心脏在暴露于过氧化氢30分钟时受到保护。单独的短暂缺血未能改变心脏对过氧化氢的反应。然而,当在核苷转运抑制剂S-(4-硝基苄基)-6-硫代鸟苷和腺苷脱氨酶抑制剂赤藓红-9-(2-羟基-3-壬基)腺嘌呤存在的情况下进行短暂缺血时,过氧化氢诱导的收缩性丧失明显减轻,且这与组织糖原含量的显著保留有关。短暂缺血/药物组合对功能变化和糖原水平的保护作用被腺苷A1受体拮抗剂8-环戊基-1,3-二丙基黄嘌呤以及ATP敏感性钾通道(KATP)阻滞剂格列本脲消除。为了进一步评估糖原在抵抗过氧化氢中的作用,我们比较了腺苷A1激动剂N6-环戊基腺苷(CPA)和胰岛素作用效果。虽然两种处理均对过氧化氢有保护作用,但胰岛素的效果优于其他任何处理。此外,虽然所有保护方式在过氧化氢处理后均保留了糖原储备,但胰岛素提供的保护还与过氧化氢给药前糖原水平的显著升高有关。在没有外源性葡萄糖的情况下,CPA或胰岛素均未表现出保护作用。综上所述,我们的结果表明,短暂缺血并同时给予增加细胞间腺苷水平的药物可保护心脏免受过氧化氢毒性。该作用由腺苷A1受体激活介导,并与KATP刺激有关。此外,我们的结果强烈提示糖原保留在赋予抗过氧化氢心脏毒性保护作用中起重要作用。